Featured News

On May 11, 2015, CDF CEO Marilyn G. Geller was proud to represent the celiac community at the public meeting of the U.S. Food and Drug Administration Functional GI Patient-Focused…

Life-Changing Opportunity for Individuals with Celiac Disease and other Gluten-Related Disorders in Pasadena, CA May 2-3, 2015 Celiac Disease Foundation (CDF) is pleased to announce that over 2,700 people –…

In the United States, an estimated three million Americans suffer from celiac disease. Due to lack of information about celiac disease manifestation, roughly 83% of Americans who experience symptoms go…

The CDF Gluten-Free EXPO was the largest yet! Nearly 3000 attendees sampled the best Los Angeles has to offer on May 2nd and 3rd. Life in LA sent their reporter to check out the exciting

On behalf of our patient community, CDF has either directly invested or fought to secure investments in diagnostics, research, and treatment for celiac disease. We have always known that this was a serious disease with broad and often devastating impacts if left undiagnosed and/or untreated. Our 25 years of hard work continues to yield returns. This is from a NY Times article published on April 29, 2015, "Pharmaceutical companies are racing to develop the first drugs for celiac disease, which researchers say is much more common than previously thought."

On May 11, 2015, the Food and Drug Administration (FDA) will conduct a public meeting on Functional GI Disorders Patient-Focused Drug Development. Celiac Disease Foundation was requested by the FDA to provide commentary about the impact of celiac disease on patients’ daily lives, the types of treatment benefit that matter most to patients, and patients’ perspectives on the adequacy of the available therapies.

Considering the rising number of cases of celiac disease, and its extremely detrimental effects on childhood development, leading to malabsorption and failure to thrive, it is becoming more necessary to find a means to properly diagnose young children.

Newly diagnosed patients with celiac disease were found to be at risk of metabolic syndrome and hepatic steatosis upon adopting a gluten-free diet. An in-depth nutritional assessment is recommended at diagnosis and during follow-up.

CDF CEO, Marilyn Geller, will present the celiac patient voice at the May 11 FDA Patient-Focused Drug Development meeting. Have your voice be heard. Complete the CDF Celiac PFDD Survey now.

Celiac Disease Foundation (CDF) – the nation’s leading disease advocacy organization for celiac disease - has received a prestigious Service Grant from The Taproot Foundation, valued at $45,000, to produce its annual report, in celebration of the Foundation’s 25th anniversary.